Pioglitazone Loaded Vesicular Carriers for Anti-Diabetic Activity: Development and Optimization as Per Central Composite Design

Haider, Md. Faheem; Kanoujia, Jovita; Tripathi, Chandra Bhushan; Arya, Malti; Kaithwas, Gaurav; Saraf, Shubhini A.

doi:10.1166/jpsp.2015.1042

Cited by 21 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Niosomes are microscopic lamellar structures ranging in size from 10 to 1000 nanometers. Surfactants are non-immunogenic, biodegradable, and biocompatible makeup niosomes [116]. The two main components employed in forming niosomes are cholesterol and nonionic surfactants.…”

Section: Niosomesmentioning

confidence: 99%

Exploring Nanocarriers as Treatment Modalities for Skin Cancer

Adnan,

Akhter,

Afzal

et al. 2023

Molecules

Self Cite

View full text Add to dashboard Cite

Cancer is a progressive disease of multi-factorial origin that has risen worldwide, probably due to changes in lifestyle, food intake, and environmental changes as some of the reasons. Skin cancer can be classified into melanomas from melanocytes and nonmelanoma skin cancer (NMSC) from the epidermally-derived cell. Together it constitutes about 95% of skin cancer. Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) are creditworthy of 99% of NMSC due to the limited accessibility of conventional formulations in skin cancer cells of having multiple obstacles in treatment reply to this therapeutic regime. Despite this, it often encounters erratic bioavailability and absorption to the target. Nanoparticles developed through nanotechnology platforms could be the better topical skin cancer therapy option. To improve the topical delivery, the nano-sized delivery system is appropriate as it fuses with the cutaneous layer and fluidized membrane; thus, the deeper penetration of therapeutics could be possible to reach the target spot. This review briefly outlooks the various nanoparticle preparations, i.e., liposomes, niosomes, ethosomes, transferosomes, transethosomes, nanoemulsions, and nanoparticles technologies tested into skin cancer and impede their progress tend to concentrate in the skin layers. Nanocarriers have proved that they can considerably boost medication bioavailability, lowering the frequency of dosage and reducing the toxicity associated with high doses of the medication.

show abstract

Section: Niosomesmentioning

confidence: 99%

Exploring Nanocarriers as Treatment Modalities for Skin Cancer

Adnan,

Akhter,

Afzal

et al. 2023

Molecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pioglitazone, a peroxisome proliferator-activated receptor (PPAR-γ agonist, increases transcription of insulin responsive genes and thus increases insulin sensitivity) falls into this class [72] . Haider et al applied the response surface methodology (RSM) to optimize particle size, entrapment efficiency and release of pioglitazone nano-formulations [73] . Formulations size varied from 145 to 500 nm, entrapment efficiency from 67% to 84% and cumulative release from 70% to 95%.…”

Section: Nano-drug Carriersmentioning

confidence: 99%

Trends of nanotechnology in type 2 diabetes mellitus treatment

Simos

Spyrou

Patila

et al. 2021

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

There are several therapeutic approaches in type 2 diabetes mellitus (T2DM). When diet and exercise fail to control hyperglycemia, patients are forced to start therapy with antidiabetic agents. However, these drugs present several drawbacks that can affect the course of treatment. The major disadvantages of current oral modalities for the treatment of T2DM are mainly depicted in the low bioavailability and the immediate release of the drug, generating the need for an increase in frequency of dosing. In conjugation with the manifestation of adverse side effects, patient compliance to therapy is reduced. Over the past few years nanotechnology has found fertile ground in the development of novel delivery modalities that can potentially enhance anti-diabetic regimes efficacy. All efforts have been targeted towards two main vital steps: (a) to protect the drug by encapsulating it into a nano-carrier system and (b) efficiently release the drug in a gradual as well as controllable manner. However, only a limited number of studies published in the literature used in vivo techniques in order to support findings. Here we discuss the current disadvantages of modern T2DM marketed drugs, and the nanotechnology advances supported by in vivo in mouse/rat models of glucose homeostasis. The generation of drug nanocarriers may increase bioavailability, prolong release and therefore reduce dosing and thus, improve patient compliance. This novel approach might substantially improve quality of life for diabetics. Application of metal nanoformulations as indirect hypoglycemic agents is also discussed.

show abstract

“…This extension of drug duration reduces the likelihood of acute and chronic complications associated with antidiabetic drugs [1]. The exploration of various nanoparticles (NPs) loaded with antidiabetic drugs, including liposomes, niosomes, polymers, dendrimers, micelles, and metal-based NPs, has been ongoing [9][10][11][12][13][14][15][16][17][18][19][20][21][22]. However, safety, tolerance, and stability challenges have been encountered [9][10][11][12][13][14][15][16][17][18][19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

“…The exploration of various nanoparticles (NPs) loaded with antidiabetic drugs, including liposomes, niosomes, polymers, dendrimers, micelles, and metal-based NPs, has been ongoing [9][10][11][12][13][14][15][16][17][18][19][20][21][22]. However, safety, tolerance, and stability challenges have been encountered [9][10][11][12][13][14][15][16][17][18][19][20][21][22]. To overcome these limitations, we propose the utilization of iron oxide-based NPs, known for their anti-in ammatory and hypoglycemic properties [23,24].…”

Section: Introductionmentioning

confidence: 99%

Managing diabetes with nanomedicine: nanoMIL-89 as a promising drug delivery system for metformin.

Mohamed,

Macasa

et al. 2024

Preprint

View full text Add to dashboard Cite

Diabetes Mellitus is a chronic disease characterized by metabolic defects, including insulin deficiency and resistance. Individuals with diabetes are at increased risk of developing cardiovascular complications, such as atherosclerosis, coronary artery disease, and hypertension. Conventional treatment methods, though effective, are often challenging, costly, and may lead to systemic side effects. This study explores the potential of nanomedicine applications, specifically Metal-Organic Frameworks (MOFs), as drug carriers to overcome these limitations. The Materials Institute Lavoisier-89 nanoparticles (nanoMIL-89) have previously demonstrated promise as a drug delivery vehicle for chronic diseases due to their anti-oxidant and cardio-protective properties. In this investigation, nanoMIL-89 was loaded with the anti-diabetic drug metformin (MET), creating MET@nanoMIL-89 formulation. We examined the drug release kinetics of MET@nanoMIL-89 over 96 hours and assessed its impact on the viability of various endothelial cells. Furthermore, we investigated the nanoformulation effect on inflammatory markers in these cells and explored its influence on phosphorylated eNOS, total eNOS, and AKT levels. Our findings indicate that nanoMIL-89 effectively released metformin over 96 hours and caused a concentration-dependent reduction in CXCL-8 release from endothelial cells. Notably, MET@nanoMIL-89 reduced dihydroethidium levels and increased phosphorylated eNOS, total eNOS, and AKT levels. Our results underscore the potential of nanoMIL-89 as a versatile potential drug delivery platform for anti-diabetic drugs, offering a prospective therapeutic approach for diabetic patients with associated cardiovascular complications.

show abstract

Pioglitazone Loaded Vesicular Carriers for Anti-Diabetic Activity: Development and Optimization as Per Central Composite Design

Cited by 21 publications

References 0 publications

Exploring Nanocarriers as Treatment Modalities for Skin Cancer

Exploring Nanocarriers as Treatment Modalities for Skin Cancer

Trends of nanotechnology in type 2 diabetes mellitus treatment

Managing diabetes with nanomedicine: nanoMIL-89 as a promising drug delivery system for metformin.

Contact Info

Product

Resources

About